Many healthcare start-ups see getting their innovation reimbursed as the ultimate goal. However, the regulations can be unclear or insufficient. We often hear that there’s no clear pathway from innovative (digital) care to reimbursed healthcare. In this session, Boris Polm, Program Manager at MedtechPartners, and Frans van Andel, Senior Specialist in Reimbursement at Seijgraaf, shed light on this reimbursement paradox influencing your innovation strategy. Who are the main decision-makers? What’s a typical path towards reimbursement under the national health insurance scheme? What’s needed when it comes to clinical data? And what are the big differences between the Dutch and Belgian health insurers?
Watch the recording